Take-home message
In this clinical practice guideline, we highlight the current evidence for management of bleeding ICU patients and areas for further research. |
Introduction
Patients admitted to the intensive care unit (ICU) frequently experience bleeding due to a variety of causes, with incidences of bleeding up to 50% reported in some ICU populations, and this in turn is associated with increased morbidity and mortality [1‐3]. While transfusion of blood products is one of the cornerstones in treatment of bleeding critically ill patients, administration of blood products also carries risks, both theoretical and measurable.
Anzeige
Challenges exist in researching bleeding in critically ill patients, particularly with the varied definitions used to describe massive and non-massive bleeding. Massive bleeding by convention can be described as greater than 10 units in 24 h or 4 units in 1 h [4]. Although difficult to manage, clinicians can readily recognize massive bleeding. However, consistent definitions in non-massive bleeding are elusive. Non-massive bleeding has clinical implication given resources and blood products required to manage these patients. To establish evidence-based interventions to reduce the resources used in non-massive bleeding, consistent nomenclature is required.
Treating bleeding in critically ill patients is a dynamic and complex process which is challenging to study, and extrapolating results from studies conducted in non-bleeding patients, or those who are less severely ill may not always be justified. Moreover, transfusion strategies during bleeding may involve multiple concurrent strategies for monitoring coagulopathy, transfusing blood products, and administering medications to support coagulation. Consequently, there is substantial worldwide variation in the treatment of critically ill patients with bleeding, and the availability of transfusion protocols in ICUs [5].
Scope and objectives of this guideline
Recognizing wide variation in transfusion practice, the European Society of Intensive Care Medicine (ESICM) created a taskforce (TF) to develop evidence-based recommendations for transfusion guidelines in the ICU and to identify knowledge gaps for future research priorities. The TF divided its recommendations into two sets of guideline recommendations. The first addressed transfusion in non-bleeding critically ill patients [6]. This manuscript includes guidelines for transfusion in critically ill patients with bleeding, including a wide variety of patient populations, not all of which are addressed in other guidelines.
The TF developed this guideline to assist critical care clinicians working in adult ICUs, with a scope including a broad set of patient populations cared for in the ICU, and transfusion-related interventions of relevance to bedside clinicians caring for bleeding patients, including use of blood products, transfusion ratios, point of care testing, and use of pharmacological agents to manage fibrinolysis (primarily tranexamic acid [TXA]). Blood pressure monitoring and targets, fluid resuscitation, vasopressor management, and bleeding source control, were considered to be beyond the scope of this guideline. Given the rapidity with which critically ill patients with bleeding can deteriorate, having a standardized approach to transfusion in these patients can be of great assistance to clinicians working in time-pressured circumstances. However, TF acknowledges that while this guideline can provide recommendations for transfusion practice in critically ill patients, specific patient characteristics and clinical circumstances may require the use of an individualized approach, integrating patient values and preferences, local resources, and patient judgement.
Anzeige
Methods
Taskforce membership
The TF included 15 clinicians with expertise in critical care medicine, anesthesiology, hematology, cardiac surgery, gastroenterology and transfusion medicine, along with methodologists experienced in guideline development using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) [7]. TF members were chosen based on their content and methodology expertise. The TF and methodologists were jointly involved in all aspects of the development of the guideline including development of PICO (population, intervention, comparison, and outcomes) questions, updating literature searches, assessing quality of evidence, formulation of recommendations, and manuscript writing. As the guideline did not have a patient representative on the panel, perspectives on patient values and preferences for transfusion and outcomes were obtained from a literature review.
Conflict of interest
At the beginning of the guideline process, and prior to submission of the manuscript, all TF members disclosed potential conflict of interest (COI). These included financial, intellectual, and personal COI. TF members were excused from voting on recommendations on any PICO questions where the TF chair considered significant COI to exist.
Sponsorship
The ESICM sponsored the development of this guideline and ESICM representatives were updated throughout the guideline process. There was no industry involvement in any aspect of the guideline.
Question development and outcome prioritization
The initial list of PICO questions was developed by the TF chairs (AV, MC). TF members were invited to submit additional PICO questions on topics related to blood product transfusions, transfusion protocols, point of care testing, and use of other medication in massively and non-massively bleeding critically ill patients. Following discussion of each PICO via teleconference, the TF voted anonymously on the questions in May 2019, using an online survey, rating the priority of each PICO on a scale of 1–10, with the highest rated PICOs being addressed in the TF guideline. The TF chose to address “massive” vs. “non-massive” bleeding separately. We used the author definitions of massive (ex. use of > 10 units of red blood cells (RBC) in 24 h or > 6 units in 6 h) and non-massive bleeding. A list of potentially relevant outcomes for each PICO question was developed at a general TF meeting (ESICM Lives 2019, Berlin, Germany). Outcomes were prioritized according to standard methods used in GRADE, using an anonymous online voting system, with each outcome being rated from 1 to 9, as “critical” (rating 7–9), “important" (4–6), or “limited importance” (1–3), according to the relative importance of each outcome to patients[8]. Critical outcomes were mortality (all-cause or bleeding-related), quality of life, functional recovery and stroke. Important outcomes included myocardial infarction, renal failure requiring renal replacement therapy (RRT), acute respiratory distress syndrome (ARDS), transfusion-related lung injury (TRALI), volume overload, venous thrombosis, length of stay (ICU and hospital), post-transfusion infections, and hemodynamic stability.
Search strategy and study inclusion
For each PICO question, a methodologist (SO) updated searches from published systematic reviews and developed new search strategies, with the input of other TF members (supplementary materials). We searched MEDLINE, EMBASE, and Cochrane databases for each PICO up to September 2019, along with trial databases (clinicaltrials.gov and ISRCTN) to identify in-progress trials, which were incorporated into the literature reviews as they became available. Search results were uploaded into Rayyan [9] for screening. Two reviewers from the TF screened the search results for relevant English-language systematic reviews (SRs), randomized controlled trials (RCTs), and observational studies. Any citation identified by either reviewer as potentially relevant underwent full text review, which were in turn also screened by two reviewers, with disagreements about inclusion at the full text resolved by discussion, with input from a third TF member.
Data abstraction and risk of bias assessment
Using a standardized, piloted data abstraction form, the methodology team conducted data abstraction for all included studies. To ensure consistency and prevent transcription errors, a second reviewer validated the data. With input from other TF members, the methodology team also conducted risk of bias assessments for each included study using the Cochrane Risk of Bias tool for RCTs [10], or the Newcastle–Ottawa risk of bias assessment tool [11].
Data analysis and rating of evidence
When there was sufficient evidence for data pooling, meta-analyses for each PICO question were conducted using RevMan v 5.3 [12]. For all outcomes, we compared fixed- and random-effects estimates, generally using fixed-effects models when the number of studies was very small (5 or fewer) or there were concerns that small-study effects may be impacting the pooled estimate; otherwise we used random-effects models [13]. For dichotomous variables, we reported relative risk (RR) and absolute risk difference (RD). For continuous variables mean difference (MD), or standardized mean difference (SMD), as appropriate, each with a corresponding 95% confidence interval (95% CI). Exploratory, post-hoc subgroup analyses were performed to explore potential sources of statistical heterogeneity (e.g. patient population, interventions, comparators, and outcomes reported). Following GRADE guidance, if unexplained heterogeneity was found, we rated down the certainty/quality of the evidence for that outcome. If heterogeneity was explainable using subgroup analysis, the panel considered this in formulating recommendations and implementation considerations. For questions in which insufficient quantitative data were available to conduct a meta-analysis, the evidence was summarized in narrative fashion.
Evidence summaries and formulation of recommendations
The methodology team (SO, JCD) developed evidence summaries for each PICO question (supplementary materials), including information on study design, population, intervention, pooled estimates of effect for each outcome, and a rating of the overall quality of evidence. We rated the certainty of evidence for each outcome as “high,” “moderate,” “low,” and “very low.” In accordance with GRADE, the task force initially categorized the certainty of evidence for each outcome as high if it originated from RCTs and low if it originated from observational data. We subsequently rated down the quality of the evidence by one or two levels if results from individual studies were at serious or very serious risk of bias [14] there were serious inconsistencies (heterogeneity) in the results across studies [15] the evidence was indirect [16], the data were imprecise [17], or publication bias was thought to be likely. Evidence from observational data could be rated upwards if effect sizes were large, there was evidence of a dose–response gradient, or all plausible confounding would either reduce a demonstrated effect or suggest a spurious effect when results showed no effect.
Anzeige
Evidence to decision (EtD) frameworks were completed by a subgroup of TF members for each PICO question to develop a draft recommendation considering the balance of desirable and undesirable effects, certainty of effects, resource considerations, feasibility, acceptability, and equity issues. While the TF planned to meet in March 2020 for final discussion and voting on the results, this meeting was cancelled in light of the coronavirus disease 2019 (COVID-19) pandemic. Instead, the TF used Panel Voice to vote on the strength and direction of the recommendation, after reviewing the EtD framework and draft recommendations created by each subgroup. A minimum of two rounds of voting were held to achieve consensus, if a consensus was not reached after two rounds a third round was held. We achieved approval on all recommendations after 2 rounds of voting. A priori, the task force chair decided that recommendations had to receive at least 80% of the vote of the panel to be approved [18].
Executive summary of recommendations: recognizing significant variation in transfusion practices to correct for anemia and/or coagulopathy in bleeding critical care patients, the ESICM assembled a task force to summarize the existing evidence regarding transfusion practices and transfusion avoidance strategies in bleeding, critically ill adults. The TF chose to address “massive” vs. “non-massive” bleeding separately. We used the author definitions of massive (ex. use of > 10 units of RBC in 24 hours or > 6 units in 6 hours) and non-massive bleeding. In addition, the task force aimed to develop clinical practice recommendations, identify knowledge gaps, and areas for future research.
Transfusion support in massively bleeding, critically ill adults
Part 1: massively bleeding patients
The following recommendations pertain to patients with massive bleeding.
1. Transfusion ratios
Recommendation | |
|---|---|
We suggest use of high-ratio transfusion strategies (at least one unit plasma per two units of packed red blood cells) vs. low-ratio transfusion strategies in critically ill patients with massive bleeding due to trauma (Conditional recommendation, low certainty of evidence). | |
We make no recommendation regarding the use of fixed high-ratio transfusion strategies in critically ill patients with non-traumatic massive bleeding (No recommendation, very low certainty evidence). |
Evidence summary
We evaluated both randomized and non-randomized evidence regarding transfusion ratios in trauma [19]. The observational trauma evidence suggests high transfusion ratios ranging from 1:1 to 1:2 fresh frozen plasma (FFP):RBC result in a large mortality benefit early on (RR 0.51, 95% CI 0.39–0.65; RD − 12.6, 95% CI − 15.7 to − 9%, very low certainty) and at 30 days (RR 0.63, 95% CI 0.54–0.73; RD − 12.6, 95% CI − 15.6 to − 9.2%, very low certainty), though these results may be confounded via survivorship bias, as in initial studies patients who lived long enough to receive thawed plasma may have been be less sick than patients who died before plasma was available. Reassuringly, in a subgroup analysis of studies excluding patients who died very early (usually within 1 h, before plasma may be available), the mortality benefit was still evident (RR 0.67, 95% CI 0.68–0.93).
Given concerns regarding residual confounding in the observational data, the panel relied primarily on evidence from the two available RCTs.[20, 21], in which high FFP: transfusion and high platelet ratios 1:1:2 compared to 1:1:1. The pooled results did not result in a mortality benefit at 24 h (RR 0.75, 95% CI 0.52–1.08; RD − 4.2%, 95% CI − 8.1 to 1.4%, moderate certainty) and 30 days (RR 0.93, 95% CI 0.72–1.2; RD − 1.7%, 95% CI − 7 to 5, low certainty), though these results were limited by imprecision. Higher transfusion ratios may result in better clinical hemostasis, reducing probability of death by exsanguination (RR 0.7, 95% CI 0.51–0.96, RD − 23.7%, 95% CI − 38.8 to − 3.2, low certainty) although certainty is limited by inconsistency between the two studies. There appeared to be no difference in rates of stroke, myocardial infarction (MI), ARDS/TRALI, congestive heart failure (CHF), infections, and venous thrombo embolism (VTE) although these results were limited by serious or very serious imprecision and cannot rule out a meaningful effect. There is moderate certainty that high transfusion ratio results in a greater proportion of patients receiving plasma (RR 1.2, 95% CI 1.01 to 1.43; mean difference 2 units, 95% CI 0.99 to 3.01) and platelets (RR 1.4, 95% CI 1.07–1.83; MD 6 95% CI 4.66–7.34), without a difference in RBCs transfused (MD 0 units, 95% CI − 1.11 to 1.11).
In non-trauma patients, we identified several observational studies, 3 in mixed populations [22‐24] 2 in cardiac and vascular surgery [23, 25], and 2 in postpartum hemorrhage [26, 27]. The overall certainty of evidence was very low for all outcomes for these groups, with limitations due to study design and imprecision. High ratio transfusion may result in more plasma transfused (MD 4.15 units, 95% CI 0.28 to 8.02), with no difference in platelets (MD 2.92, 95% CI − 2.52 to 8.36) or PRBCs (0.49, 95% CI − 2.55 to 3.52), though certainty of evidence is very low.
Justification
Although the large reduction in mortality with the use of higher ratios seen in observational studies is more modest (and only seen for early death due to exsanguination) and less precise in the RCTs, it is reassuring that the direction and magnitude of the effects are similar, showing a reduction in early and late mortality with high-ration transfusion strategies. Additionally, the improved hemostasis demonstrated in the PROPPR trial [20] provides a sensible mechanism by which high-ratio transfusion could prevent deaths, this could be driven by the higher number of platelets received. Very few undesirable clinical effects were seen leading the panel to determine that even if of uncertain magnitude, the desirable effects likely outweigh the undesirable effects. It should be noted that few undesirable clinical effects were seen, the investigators did not seek to explore these at the initiation of the study. Due to the lack of certainty for many outcomes, along with the resource implications for increased use of plasma and platelets, the panel chose to make a conditional recommendation for fixed, high-ratio transfusion in trauma patients with massive bleeding.
The panel decided on the basis of the limited existing evidence that no recommendation for or against the use of fixed high-ratio transfusion could be made outside of the trauma setting, especially given potential differences in pathophysiology and coagulopathy compared to non-traumatic bleeding, and the resource implications of increased plasma and platelet transfusions.
Implementation issues
The PROPPR [20] and Nascimento [21] studies compared high RBC: plasma:platelets ratios 1:1:1 transfusion ratios to a low ratio of 2:1:1, or transfusion guided by coagulation testing. If a fixed high-ratio transfusion approach is used, the 1:1:1 ratio is the most reasonable approach to initiate empiric transfusion when massive hemorrhage is suspected. Although the panel chose not to make a recommendation regarding fixed-dose transfusion ratios outside of the setting of trauma, many centers have developed massive transfusion protocols to cover all clinical scenarios, based upon extrapolation from the trauma literature. While the TF judged that the existing evidence does not support high-ratio transfusion outside of trauma, there may be important clinical impacts from the use of standardized massive transfusion protocols, beyond the effects of altered transfusion ratios alone, such as having a coordinated and efficient response to acute bleeding [28].
2. Platelets
Recommendation | |
|---|---|
We make no recommendation regarding the use of cryopreserved or cold-stored platelets in bleeding patients with massive or non-massive hemorrhage (No recommendation, very low certainty of evidence). |
Evidence summary
There is little evidence regarding the use of cryopreserved or cold-stored platelets for the treatment of hemorrhage in comparison to conventionally stored (room temperature, 20–24 °C), “standard” platelets. We identified two small studies, one comparing cryopreserved platelets to standard platelets and one comparing cold-stored platelets to standard platelets.
The first study was a single center non-randomized observational study of standard (fresh apheresis) platelets and cryopreserved platelets (frozen at −80 °C and later reconstituted in thawed plasma) in a broad set of hemorrhaging patients [29]. Multiple clinical outcomes were evaluated, including 30-day survival, overall blood product use, TXA and fibrinogen concentrate use, and adverse events. There was no appreciable difference in 30-day mortality (RR 1.26, 95% CI 0.41–3.88; RD 5%, 95% CI − 11.2 to 5.49; very low certainty) or other outcomes.
The second study was a single center two-stage pilot RCT of the use of cold-stored (2-6 °C) platelets adult cardiothoracic surgery patients; the first stage utilized platelets stored in the cold for up to 7 days, while the second stage utilized those stored in cold for 8–14 days [30]. The primary outcome reported was the difference in median blood loss (as measured by chest drain output): the difference in median blood loss between room temperature and cold-stored up to 7 days was − 216 ml (95% CI − 465.7 to 33.68, very low certainty); the difference between room temperature and cold-stored for 8–14 days was 986 mL (95% CI − 296.13 to 2268.1, very low certainty). Secondary outcomes (total blood usage, adverse events, ICU length of stay, mortality) were comparable among those receiving cold-stored and standard platelets, but the number of events was very small in this pilot study.
Justification
Despite similarities in nomenclature, cryopreserved and cold-stored platelets are dissimilar blood products, and the rationale for their preparation and use equally dissimilar. Cryopreserved platelets are intended to have a substantially longer shelf-life than standard apheresis platelets (years versus days), thus reducing potential limitations in the platelet supply and providing products where and when standard platelets are not available. Cold-stored or cryo-stored platelets, on the other hand, have potentially longer shelf-lives than standard units and, based on in vitro and preliminary clinical studies, may be more hemostatically active than their room-temperature counterparts. The TF identified two published clinical studies on the use of these products compared to standard platelets, and despite the fact that each study did not demonstrate results unfavorable to cryopreserved or sold-stored platelets, both had sample sizes that were too small to provide anything beyond a very low degree of certainty in their results. Therefore, while both cryopreserved and cold-stored platelets are theoretically appealing, it was judged that there was insufficient evidence to make a recommendation for or against their use in the bleeding patients.
3. Prothrombin complex concentrate and plasma
Recommendation | |
|---|---|
We make no recommendation for the use of PCC versus plasma alone in massively bleeding patients due to very low certainty of evidence from observational studies only (No recommendation, very low certainty of evidence). |
Evidence summary
For all patient populations, only observational studies were included in the analysis [31‐35]. Thereby, risk of bias is high, most importantly related to a mismatch in disease severity. For cardiac surgery, none of the relevant patient outcomes differed between arms. There is a reduction in RBC transfusions in favour of the PCC arm, but chest tube output was not different. For trauma, pooling of data suggests a decrease in mortality, but this was found in a single study only. Of note, all trauma studies reported a decrease in transfusion requirements in the PCC arm, which is congruent with a mortality benefit. However, there were considerable differences in the comparator arms, hampering any recommendation. For liver transplant and TBI, there was insufficient data. Taken together, there is insufficient data on efficacy and safety of PCC in all categories of bleeding patients. With the lack of evidence and concern for safety, PCC use should be reserved for clinical trials.
Justification
There was no clear signal of harm, in particular no increase in thromboembolic events in the PCC arm; however, this is based on very low certainty of evidence. Thereby, we do not recommend against the use of PCC. However, it is not clear how robust the data were gathered, hampering the weighing of benefit and harm. Other concerns that preclude a recommendation to use PCC relate to cost-effectiveness and to a lack of knowledge on potential conflict of interest related to funding sources of the included studies.
Research priorities
The TF rated optimal management of massive bleeding as a clear priority. The very low level of evidence of benefit across all patient populations as well as the absence of harm of PCC, point towards a strong research priority assessing the efficacy and safety of the use of PCC in the treatment of bleeding.
4. Fibrinogen
Recommendation | |
|---|---|
We make no recommendation regarding the use of early empiric fibrinogen replacement in critically ill patients with massive hemorrhage due to trauma (No recommendation, low certainty evidence). |
Evidence summary
In patients with massive bleeding due to trauma, it is unclear whether or not early, empiric fibrinogen administration is beneficial, compared to a strategy of fibrinogen replacement once hypofibrinogenemia is documented. The 5 RCTs [36‐39] identified are small, with inconsistent and imprecise impact upon overall mortality (RR 1.02, 95% CI 0.33–3.11; RD 0.3%, 95% CI − 10.3 to 32.6, low certainty) and deaths due to hemorrhage (RR 0.77, 95% CI 0.27–2.18; RD − 2.3%, 95% CI − 7.4 to 12, low certainty). The impact upon other patient outcomes, including transfusion requirements are similarly unclear, without any clear signal for harm nor benefit.
Justification
While observational studies demonstrate a relation between hypofibrinogenemia and coagulopathy as well as with adverse outcome of bleeding due to trauma [40‐42], thus providing a strong theoretical rationale for supplementation of fibrinogen during bleeding, clinical evidence for early fibrinogen supplementation remains unclear. The existing RCTs demonstrate that it is feasible to increase fibrinogen levels and FIBTEM values with fibrinogen concentrates, suggest that fibrinogen may reduce transfusion needs in patients with a low fibrinogen level, but the impact of an early/empiric fibrinogen replacement strategy compared to one guided by coagulation testing remains unclear. Similarly, the ideal, fibrinogen dose and target level are not clear. Observational studies in trauma suggest a relation with low levels and mortality; conversely a possible association between higher fibrinogen levels and mortality [42] as well as with thrombosis [43]. More evidence is need regarding empirical and lab-based supplementation before a recommendation for or against early fibrinogen can be made; at the present time, either approach is justifiable on theoretical grounds.
Implementation issues
If a fibrinogen-based strategy is chosen, studies in trauma suggest that this would confer the greatest benefit in those with low fibrinogen lab values; however, this threshold may be different in other populations; thus, if an early fibrinogen replacement strategy is used, it would ideally incorporate rapid laboratory testing to guide clinicians on when empiric fibrinogen should not be used.
5. Point of care testing
Recommendation | |
|---|---|
We suggest for either for viscoelastic or conventional coagulation assays to guide transfusions in massively bleeding trauma critically ill patients (Conditional recommendation, low quality of evidence). |
For evidence summary and justifications, please see below section on point of care testing.
Part 2: transfusion support in non-massively bleeding critically ill adults
1. RBC transfusion
Recommendation | |
|---|---|
In patients with non-massive bleeding after vascular surgery, we suggest restrictive (7.5–8 g/ d/L) red blood cell transfusion threshold (Conditional recommendation, low certainty). |
Evidence summary
A single RCT [44] of patients undergoing vascular surgery evaluated a restrictive (8 g/dL) vs. liberal (9.7 g/dL) transfusion strategy in patients with bleeding. Due to the small number of events in the study, the results were very imprecise for most outcomes, including mortality (RR 2, 95% CI 0.19–20.86; RD 3.4, 95% CI − 2.8 to 68.5, low certainty) and myocardial infarction (RR 1, 95% CI 0.15–6.63; MD 0, 95% CI − 5.9–38.8, low certainty). A restrictive transfusion threshold appeared to result in lower number of transfusions (MD 2 units, 95% CI 3.22–0.78, high certainty) and proportion of patients receiving transfusions (RR 0.66, 95% CI 0.51–0.86, high certainty), without a significant reduction in the risk of transfusion reactions (RR 0.33, 95% CI 0.01–7.86, very low certainty).
Justification
The existing evidence does not demonstrate important clinical benefits or harms with restrictive vs liberal transfusions in vascular surgery patients, beyond reductions in red cell transfusion, with all estimates having low certainty because of the very small number of events, resulting in very serious imprecision. The absence of evidence for a treatment effect on clinically important outcomes, reduces the likelihood that patient values and preferences will have a role on decision-making. However, it is still expected that most patients would choose not to have a transfusion if it does not improve symptoms or other outcomes.
Implementation issues
The restrictive threshold suggested by the TF includes a slightly higher range than that recommended for most populations in part 1 of the guideline, including the recommendation for a restrictive transfusion threshold of 7.5–8 g/dL recommended for patients undergoing cardiac surgery, a population of similar age and with similar vascular comorbidities. This difference reflects the thresholds studied in the available clinical trials, but also reflects the significant cardiovascular comorbidities in this patient population, and clinical uncertainty given the limited direct evidence available to guide practice. As a result, there may remain some variability in how clinicians implement this restrictive strategy, based upon the volume of bleeding, ease of definitive hemorrhage management, presence of active cardiac disease, and patient symptoms.
Recommendation | |
|---|---|
In patients with non-massive postpartum hemorrhage, we suggest restrictive transfusion, guided by presence of shock and symptoms potentially attributable to anemia (e.g. dyspnea, syncope, tachycardia, angina, neurological symptoms) or hemoglobin < 6 g/dL, rather than at a liberal target hemoglobin of 9 g/dL (Conditional recommendation, low certainty). |
Evidence summary
A single randomized controlled trial [45] of anemic postpartum patients with a hemoglobin (Hb) of 49–79 g/L found that that a restrictive red cell transfusion strategy guided by patient symptoms compared with liberal transfusion target (Hb > 89 g/L) may result in no difference in terms of quality of life, measured by SF-36 questionnaire (MD 0.1, 95% CI − 3.5 to 3.3, low certainty), incidence of venous thrombosis (RR 0.99, 95% CI 0.14 –6.97, low certainty), post-transfusion sepsis or infection (RR 1.08, 95% CI 0.62–1.87, low certainty), or transfusion reactions (RR 0.14, 95% CI 0.01–2.72, very low certainty). There were moderate resource savings associated with reducing blood transfusion, including reduced mean number of transfusions (MD 2 units) and mean cost reduction of € 249 in the restrictive threshold arm.
Justification
Evidence related to quality of life, although of critical importance in this particular cohort of patients, had to be rated as low certainty due to the lack of blinding at the time of assessment of the SF-36 questionnaire. Imprecision related to the reporting of post-transfusion sepsis and hospital-associated venous thromboembolism resulted in a low level of certainty in the pooled effects, while the number of transfusion reactions was very small, resulting in a very low level of certainty for very serious imprecision. Given the lack of clear evidence that liberal transfusion improves outcomes, including quality of life, and the increased use of blood products required, the panel chose to issue a conditional recommendation for restrictive transfusion for symptomatic patients only [45] (e.g. dyspnea, syncope, tachycardia, angina, neurological symptoms), along with a lower asymptomatic limit of 6 g/dL Hb to ensure ‘buffer’ in the event of unrecognized ongoing hemorrhage.
Implementation issues
Evidence in this setting is limited to a single trial, creating some concerns around the acceptability of a restrictive threshold for RBC transfusion, in particular whether there is a lower limit. In patients with minor hemorrhage, no symptoms, the decision to transfusion can be discussed with the patient, as preferences may vary. The TF suggested a restrictive transfusion threshold which is consistent with guidance from other societies, including the Royal College of Obstetricians and Gynaecologists [46, 47] which adopt both clinical and hematological criteria to guide the decision to perform blood transfusion. In patients with severe shock, uncontrolled bleeding a higher threshold may be considered, anticipating ongoing blood loss.
Recommendation | |
|---|---|
In patients with non-massive gastrointestinal bleeding, we suggest restrictive (7 g/dL) transfusion vs. liberal (9 g/dL) red blood cell transfusion threshold (Conditional recommendation, moderate certainty). |
Evidence summary
A total of four RCTs [48‐51] were identified that examined the impact of a restrictive versus a liberal transfusion strategy. A restrictive transfusion strategy led to a reduction in mortality (RR 0.63, 95% CI 0.43–0.93), risk of rebleeding (RR 0.61, 95% CI 0.46–0.81), and volume overload (RR 0.13, 95% CI 0.03–0.54). There was also an improvement in quality of life measured using EQ5D (MD 0.07, 95% CI 0.02–0.12) with a restrictive strategy. There was no effect with regards to stroke (RR 0.56, 0.29 to 1.09), myocardial infarction (RR 0.62, 95% CI 0.26–1.47), post-transfusion sepsis (RR 0.95, 95% CI 0.81–1.13). There may be moderate cost saving with reduced risk of bleeding because of reduced number of patients requiring transfusion. There are no formal studies evaluating a restrictive versus liberal transfusion strategy in patients with gastro intestinal bleeding (GIB); however, with decreased number of transfusion and better outcomes, a restrictive strategy may be a cost-effective strategy.
Justification
The certainty of evidence for rebleeding, hospital length of stay, mean number of transfusions and proportion of patients receiving transfusion and mortality, stroke, volume overload consisted of moderate certainty of evidence. In comparison, there was low certainty of evidence for quality of life, myocardial infarction, acute kidney injury and transfusion reactions. Evidence was rated down for imprecision due to the low event rate, target sample size not met, and wide confidence interval. Overall, gastrointestinal (GI) bleeding patients, the panel had moderate certainty that a restrictive transfusion strategy is safe, and possibly results in improved outcomes, with fewer resources.
Implementation issues
There are no significant implementation considerations as the studies included those with gastrointestinal and portal hypertensive bleeding.
2. Platelets
Recommendation | |
|---|---|
We make no recommendation for the use of a restrictive vs a liberal platelet transfusion threshold in non-massively bleeding patients with thrombocytopenia (No recommendation, very low certainty evidence). |
Evidence summary
We identified only one retrospective cohort study examining platelet transfusion in thrombocytopenic patients who had intracranial hemorrhage (ICH)[52] and had a platelet transfusion. The study had two cohorts (1) participants with ICH with reduced platelet activity based on the aspirin response test who received platelets (2) participants with ICH who received platelets. Each cohort was compared to aspirin responders and participants with ICH who did not receive platelets; outcomes examined included hematoma volume and expansion. There was no effect in hematoma size (RR 0.71, 95% CI 0.34–1.47) or expansion (RR 1.44, 95% CI 0.92–2.24, very low certainty) [52].
Justification
The evidence is of very low certainty due to the absence of studies evaluating platelet transfusion thresholds in bleeding patients with thrombocytopenia. The clinical effects and resource implications of higher vs lower platelet transfusion thresholds in bleeding patients are unclear. As a result, the TF did not make a specific recommendation of transfusion thresholds for patients with non-massive bleeding.
Implementation issues
We make no recommendation for the use of a restrictive or a liberal platelet transfusion threshold in bleeding patients with thrombocytopenia, and as such either strategy could be considered based on individual patient characteristics. However, recommendations made in Part 1 of the guidelines set lower limits after which prophylactic platelet transfusion should be considered, irrespective of bleeding.
Recommendation | |
|---|---|
We suggest using a restrictive platelet transfusion strategy (no transfusion) in patients with intracranial hemorrhage (spontaneous or traumatic intracerebral hemorrhage) who are on antiplatelet therapy (Conditional recommendation, moderate certainty evidence). | |
We make no recommendation for the use of a restrictive (no transfusion) vs liberal platelet transfusion strategy in critically ill patients with non-massive bleeding who are on antiplatelet therapy (No recommendation, very low certainty of evidence). |
Evidence summary
Two randomized trials have investigated platelet transfusion in patients on antiplatelet therapy with spontaneous intracranial hemorrhage (ICH), neither finding a benefit with platelet transfusion [52, 53].The PATCH trial [53] included 190 non-thrombocytopenic patients with ICH, with a Glasgow Coma Scale (GCS) score > 8 who had received antiplatelet medications. The composite endpoint of death or dependence at 3 months was higher in patients receiving platelet transfusion than in those who did not (RR 2.05, 95% CI 1.18–3.56, p = 0.014), there was no significant difference in the individual outcomes including mortality. The second RCT compared post-surgical hemorrhage in patients with antiplatelet therapy and who underwent craniotomy for acute ICH, finding liberal platelet transfusion (in comparison to restrictive platelet transfusion) was not associated with a difference in post-surgical bleeding volume. Overall, the pooled evidence from these two RCTs, suggests there is no difference in mortality at 3 months (RR 0.71, 95% CI 0.44–1.14) overall mortality (RR 0.84, 95% CI 0.58–1.22), disability at 3 months or by the ADL, or bleeding volume.
We identified only one retrospective single center study comparing platelet transfusion strategies in patients on antiplatelet agents with non-massive bleeding for ICH [54]. This was a case control study in patients with GI bleeding, patients who did not receive platelet transfusion had a lower mortality (RR 0.21, 95% CI 0.06–0.73), less cardiac event (RR 0.55, 95% CI 0.31–0.98) and lower recurrent bleeding (RR 0.71, 95% CI 0.56–0.9).
Justification
Antiplatelet therapy effect lasts for up to 10 days leading to an increase in hemorrhage occurrence and severity. Observational studies have reported a poorer outcome in patients with ICH receiving antiplatelet therapy. Transfusion of platelets in this setting might offset antiplatelet therapy effect, improve hemostasis and outcome. However, the two existing RCTs [52, 53] reported similar, or possibly worse outcomes in patients receiving platelet transfusions. Given the lack of evidence for any desirable effects, the possible adverse effects related to platelet transfusion, the cost of transfusion and the fact that platelets are a limited resource, the panel made a conditional recommendation to not administer platelets in patients on antiplatelet agents with ICH.
The PATCH Trial [53] did included patients with ICH who have a GCS > 8 which may limit the generalizability to ICU patients. There is even less evidence to guide platelet transfusion decisions in critically ill patients with non-massive bleeding other than ICH and on antiplatelet agents. While patients on antiplatelet therapy are at higher risk of GI bleeding and higher risk of severe bleeding and recurrent bleeding. However, cease of antiplatelet therapy or platelet transfusion might expose patients to major cardiac events including myocardial infarction. The benefit of one or the other platelet transfusion strategy might be impacted by the source of bleeding (ulcerous, variceal upper GI bleeding, colonic). Given the substantial uncertainties, we did not make a recommendation for or against platelet transfusion for critically ill patients on antiplatelet agents with bleeding other than ICH.
Implementation issues
Given the lack of evidence, decisions about transfusing platelets in patients on antiplatelet agents need to be based upon individual considerations, including the severity and location of bleeding, consideration of risks of transfusion, and availability of blood products. Enthusiasm for platelet transfusion should be tempered given the lack of benefit in ICH, in which even small difference in hemorrhage volumes would be expected to have an impact upon patient outcome; the benefit in other populations is likely to be even less certain.
3. Fibrinogen
Recommendation | |
|---|---|
We suggest the empiric use of fibrinogen concentrate in critically ill patients with non-massive bleeding after cardiac surgery, using either fixed dose (2–4 g) or titrated to FIBTEM clot firmness, to maintain a fibrinogen level over 1.5 g/dL necessary for clot formation and platelet aggregation, after giving the empiric fibrinogen dose if available [55] (Conditional recommendation, low certainty of evidence). | |
We make no recommendation regarding the empiric use of fibrinogen concentrate in other critically ill patients with non-massive bleeding (No recommendation, low certainty of evidence). |
Evidence summary
We identified six RCTs evaluating the use of fibrinogen in patients with non-massive bleeding after cardiac surgery one comparing fibrinogen to FFP in major vascular surgery, and one comparing fibrinogen concentrate plus FFP to FFP alone in a mixed surgical population [56‐62]. In cardiac surgery, the point estimate for mortality favours the use of fibrinogen, however, the number of events is small, resulting in very serious imprecision (RR 0.44, 95% CI 0.17–1.19; RD − 2.9% 95% CI − 4.3 to 1, low certainty). Fibrinogen likely results in a reduction in blood loss (MD − 88 mL, 95% CI − 149 mL to 26 mL, moderate certainty) and may reduce the need for RBC transfusion (RR 0.62, 95% CI 0.46–0.84; RD − 18%, 95% CI − 25.7 to 7.6%, low certainty), plasma transfusion (RR 0.44 95% CI 0.22–0.90; RD − 10%, 95% CI − 13.9 to − 1.8%, low certainty), and platelet transfusion (RR 0.5, 95% CI 0.29–0.86; RD − 10.5, 95% CI − 15.0 to − 3%, low certainty) without impact upon other outcomes, including stroke, MI, AKI, venous thrombosis, infections, and length of stay. In the two small non-cardiac surgery studies, the number of events was small, and overall certainty of evidence was low due to very serious imprecision [58, 63].
Justification
The use of fibrinogen in patients with bleeding after cardiac surgery results in reductions in blood loss and use of blood products which are cost-effective; however, impact upon other patient-important outcomes, including mortality, is unclear. The TF determined there was insufficient evidence to provide guidance regarding the use of empiric fibrinogen concentrate in non-massive bleeding outside of the context of cardiac surgery.
Implementation issues
Fibrinogen is vital for the clot formation and platelet aggregation; the dose of fibrinogen varied between studies, ranging between 1 and 4 g, and used varied targets, [56] FIBTEM clot firmness [58‐61], or fixed-dose [57, 62, 63]. These studies used clinical bleeding as the trigger to initiate administration of fibrinogen concentrate rather than coagulation testing or FIBTEM. Once coagulation test results are available, they can be used alongside clinical assessment of bleeding to guide decisions about further fibrinogen administration. While ideal fibrinogen targets are unclear, it would be reasonable to maintain a fibrinogen level over 1.5 g/dL necessary for clot formation and platelet aggregation, after giving the empiric fibrinogen dose [55].
Fibrinogen concentrate may not be available in all centers, in which case cryoprecipitate may be a reasonable alternative. While the recent FIBRES trial suggests that outcomes between fibrinogen concentrate and cryoprecipitate are similar in patients with cardiac-surgery-related bleeding-related to hypofibrinogenemia [64], rapid administration of fibrinogen administration in bleeding patients may be more easily achieved, as storage and reconstitution of the product (concentrate) is likely easier from a logistical standpoint compared to cryoprecipitate.
4. Plasma
Recommendation | |
|---|---|
We make no recommendation for a restrictive plasma versus a liberal plasma transfusion strategy for non-massively bleeding patients with or without coagulopathy (No recommendation, low certainty evidence). |
Evidence summary
The panel sought evidence comparing liberal/empiric use of plasma to restrictive plasma transfusion, or no transfusion, in non-massively bleeding platelets. One RCT [36] was identified that evaluated the use of plasma in 90 blunt trauma (injury severity score > 16) patients who received RBCs transfusion and had a fibrinogen level < 5.88 g/L [36]. Patients were randomized to receive: 1) fibrinogen, 2) FFP (2 units), or 3) RBC transfusion alone. This study included non-massively bleeding patients, with a mean RBC transfusion requirement of 2 ± 1.1 (fibrinogen group), 2.7 ± 0.7 (FFP group) and 2.9 ± 0.9 (control group). There was no difference in mortality (RR 1, 95% CI 0.51–1.94), multiorgan failure (RR 0.88, 95% CI 0.36–2.11) or length of stay (MD 4.4., 95% CI 0.4–8.4) between restrictive and liberal plasma transfusion group (RR 1, 95% CI 0.51–1.94). More sepsis (RR 0.25, 95% CI 0.09–0.66) occurred in the liberal transfusion group. Considering the study groups, it is unclear whether plasma is due to fibrinogen effect and not plasma alone. More evidence is needed for the use of plasma infusions in non-massively bleeding patients. The basic science literature is emerging with a potential new resuscitation target of restoration of endothelial glycocalyx (EG) [65], in rat models of hemorrhagic [65] and septic shock improved survival with FFP compared resuscitation with crystalloids [66] with restoration of EG.
Justification
The use of a liberal plasma transfusion strategy incorporating 2 empiric units of FFP in non-massively bleeding trauma patients did not demonstrate any benefit but did raise the possibility of harm (e.g. sepsis). However, this data is from one small RCT [36] and is of low certainty, limited by imprecision and risk of bias. The panel thus made no recommendation for plasma transfusion in patients without massive bleeding, or coagulopathy.
5. Point of care vs. conventional coagulation testing
Recommendation | |
|---|---|
We suggest either viscoelastic testing or conventional coagulation testing to guide transfusions in massive and non-massively bleeding cirrhotic patients, liver transplant patients or critically ill trauma patients (Conditional recommendation, low certainty evidence). |
Evidence summary
In massively bleeding cirrhotic patients, based on two RCTs [67, 68], there was uncertainty as to the effects of the implementation of viscoelastic on mortality (RR 0.82, 95% CI 0.59–1.13, low certainty), rebleeding (RR 0.71, 95% CI 0.47–1.07, very low certainty), transfusion associated cardiac overload (RR 0.48, 95% CI 0.18–1.3, low certainty) and red cell transfusion (RR 1.06, 95% CI 0.67–1.68, low certainty). In these trials, there was evidence that the use of viscoelastic testing may reduce transfusion associated lung injury (RR 0.25, 95% CI 0.11–0.56, low certainty), acute respiratory distress syndrome (RR 0.11, 95% CI 0.01–0.81, low certainty), platelet transfusion (RR 0.14, 95% CI 0.05–0.43, low certainty) and fresh frozen plasma transfusion (RR 0.29, 95% CI 0.11–0.77, low certainty).
In massively bleeding liver transplant patients, based on the evidence pooled from a Cochrane Systematic review [69] and an observational study [70], there was uncertainty as to the effects of viscoelastic on mortality (RR 0.67, 95% CI 0.13–3.4, low certainty), red cell transfusion (MD − 12.22, 95% CI − 71.08 to 46.64, very low certainty) and platelet transfusion (MD − 2.8, − 14.92 to 9.32, very low certainty). There was, however, evidence that elastic may result in less blood loss (MD -1.13, 95% CI − 1.85 to − 0.41, very low certainty) and FFP Transfusion (MD − 8.7, 95% CI − 16.3 to − 1.1, very low certainty) in massively bleeding liver transplant patients.
In massively bleeding critically ill trauma patients, in a randomised trial [71], the use of viscoelastic testing did not result in a significant mortality reduction (RR 0.54, 95% CI 0.29–1.02, very low certainty).
Justification
Even though the positive effects of viscoelastic testing on a limited number of outcomes such as TRALI and ARDS might be moderate (in particular in the cirrhotic population), the limited number of studies, the substantial heterogeneity, the wide confidence intervals, and the imprecision in the estimates, determine the overall low confidence in the certainty of these results. These observations are applicable to all subgroups but are especially true in the case of trauma patients.
Recommendation | |
|---|---|
We suggest either viscoelastic testing or conventional coagulation testing to guide transfusions in bleeding cardiac surgery patients (Conditional recommendation, very low certainty of evidence). | |
We suggest using either viscoelastic testing or conventional coagulation testing to guide transfusion in extra corporeal membrane oxygenation (ECMO) patients with non-massive bleeding (Conditional recommendation, very low certainty evidence). |
Evidence summary
In non-massively bleeding cardiac surgery patients, based on two recent systematic reviews [72, 73], there is uncertainty as to the effects of viscoelastic on mortality (RR 0.6, 95% CI 0.34–1.07, low certainty), and hospital length of stay (RR 0.86, 95% CI 0.76–0.98, very low certainty). There was evidence of reductions in the risk of red cell transfusion (RR 0.86, 95% CI 0.76–0.98, low certainty), platelet transfusion (RR 0.68, 95% CI 0.46–0.99, very low certainty), and fresh frozen plasma transfusion (RR 0.46, 95% CI 0.37–0.57, very low certainty). Viscoelastic also resulted in reductions in 12-h postoperative bleeding (MD − 128.18mls, 95% CI − 172.38 to − 83.97, very low certainty), in 24-h postoperative bleeding (MD − 175.25 mls, 95% CI − 305.19 to − 45.32, low certainty), and ICU length of stay (MD − 4.08 h, 95% CI − 6.33 to − 1.82, very low certainty), although the clinical importance of these effects is unclear.
Based on the pilot randomized controlled trial by [74] the implementation of viscoelastic in managing non-massively bleeding ECMO patients may not result in any difference in mortality (RR 0.86, 95% CI 0.13–3.4, low certainty), rebleeding (RR 0.43, 95% CI 0.12–1.51, very low certainty), or thrombotic complications (RR 0.2, 95% CI 0.03–1.39, very low certainty).
Justification
There is uncertainty as to the effects of viscoelastic in non-massively bleeding cardiac surgery patients on clinically important outcomes. Most treatment effects were observed in outcomes that are particularly susceptible to performance bias, are of limited importance to patients, and demonstrated high heterogeneity. Moreover, most studies included in the systematic review [72, 73], were at unclear or high risk of bias. Two studies [75, 76], assessed the resource requirements and cost-effectiveness of this technology in the cardiac surgery population suggesting small cost savings over usual care, but substantial uncertainty remains. The single RCT [74] in patients undergoing ECMO provides only very low certainty evidence for the differences between viscoelastic testing and conventional coagulation testing.
Implementation issues
Despite the very low certainty provided by the available evidence, many centers have adopted the use of viscoelastic testing to guide transfusions, due to perceived efficiency, specificity, and rapidity of testing. However, for centers without viscoelastic testing, resource considerations and staff education needs, would likely play a role in deciding whether it should be adopted, in light of the limited evidence available regarding its impact upon patient outcomes and blood product use.
Part 3. Tranexamic acid (TXA) in bleeding critically ill adults
TXA in patients with traumatic intracranial hemorrhage
Recommendation | |
|---|---|
We recommend the use of early (< 3 h from trauma) TXA in critically ill patients with bleeding or suspected bleeding due to trauma (Strong recommendation, high certainty). |
Evidence summary
The landmark multi-centre CRASH-2 RCT demonstrated that administration of TXA results in a reduction of death (RR 0.91, 95% CI 0.85–0.97; RD − 1.4%, 95% CI − 2.4 to − 0.5, high certainty), with no difference in venous thrombosis, stroke, myocardial infarction or need for surgical intervention [77]. The risk of seizures was not reported, though reassuringly no increase in seizures was noted in the CRASH-3 study, which evaluated the use of TXA in trauma patients with isolated traumatic brain injury [78].
Justification
Compared to placebo, TXA results in small but clinically meaningful reductions in bleeding death and overall mortality, with trivial undesirable effects. TXA is inexpensive, likely cost-effective, [79] acceptable, and feasible to implement in most settings.
Implementation issues
The dose of TXA given in CRASH-2 was a loading dose of1 g IV over 10 min, followed by 1 g IV over 8 h. While some centers may use point of care testing (e.g. TEG/ROTEM) to guide management of bleeding patients, the task force recommends early empiric use of the loading dose of TXA prior to such testing as point of care measurements have varying sensitivity for identifying hyperfibrinolysis [80] and earlier administration of TXA may be more effective at reducing mortality [81]. However, to date there is limited evidence to guide the use of very early, prehospital administration of TXA [82].
Recommendation | |
|---|---|
We suggest the use of TXA in critically ill patients with acute traumatic brain injury and bleeding due to trauma (Conditional recommendation, moderate certainty). |
Evidence summary
A recent systematic review identified 9 RCTs which reported all-cause mortality, including unpublished data from CRASH-3, reporting that TXA does not reduce all-cause mortality (RR 0.95, 95% CI 0.88–1.02; RD − 1%; 95% CI − 2.5 to 0.4%, moderate certainty) or disability as assessed with the disability rating scale (MD − 0.18, 95% CI − 0.43 to 0.08, moderate certainty [83]. Data from the largest trial, CRASH-3, suggests that TXA may reduce head-injury associated death when excluding patients with severe traumatic brain injury (TBI) whom are unlikely to survive with or without treatment (Glasgow Coma Score of 3 or bilateral unreactive pupils at baseline) (RR 0.89, 95% CI 0.8 to 1; RD -1.5 95% CI -2.8 to 0.4%). There appears to beno effect on risk of stroke, MI, venous thromboembolism, sepsis, surgical intervention, or seizure.
Justification
The use of TXA may not result in a reduction in mortality or disability in all patients, but there may be a reduction in head-injury-related mortality in patients who have mild to moderate TBI, as well as a reduction of progression of intracranial hemorrhage. Although the clinical relevance of these findings is unclear, most patients would likely accept TXA, given the demonstrated safety profile of TXA in this population, the possibility of concomitant non-head injuries for which TXA is indicated as per the previous recommendation, and the low cost and acceptability and feasibility of the intervention. Given the lack of certainty around patient-important effects, the panel chose to make a conditional recommendation for the use of TXA in this population.
Implementation issues
All studies used similar dosing to CRASH-2, with 1 g IV TXA loading dose followed by an infusion of 1 g IV maintenance infusion over a longer period of time. Some patients with TBI have other associated traumatic injuries; this recommendation supports the use of TXA in trauma with or without TBI, while the severity and nature of injuries is being assessed. As in the general trauma population, there is a suggestion that if TXA is given, it is most likely to be effective when given early, within 3 h although the prehospital may not be more effective [78, 84]. While some centers may use viscoelastic testing to guide interventions, early empiric use of TXA may still be beneficial, as point of care results may not be sensitive for hyperfibrinolysis [80].
Recommendation | |
|---|---|
We make no recommendation regarding the use of TXA in critically ill patients with subarachnoid hemorrhage (No recommendation, low certainty evidence). |
Evidence summary
A number of trials have evaluated anti-fibrinolytic therapies in patients with aneurysmal subarachnoid hemorrhage (SAH), 10 of which evaluated IV TXA [85‐94]. These studies demonstrated no change in mortality (RR 1.01, 95% CI 0.88–1.16;RD − 0.3%, 95% CI − 3.2 to 4.2%, moderate certainty) or poor functional outcome (RR 1.05, 95% CI 0.95–1.15; RD − 0.4%, 95% CI − 1.9 to 5.8, low certainty), but a reduced risk of rebleeding (RR 0.6, 95% CI 0.44–0.8; RD − 7.8%, 95% CI − 11 to − 3.9, moderate certainty), offset by an increased risk of stroke (RR 1.29, 95% CI 1.01 to 1.67; RD 6.1%, 0.2% to 14.1%, low certainty). Only the recent ULTRA trial reported rates of venous thrombosis, which were rare but similar between groups [90]. Most trials were several decades old, with only the three most recent trials evaluated TXA within clinical context with the use of calcium channel blockers and endovascular coiling of aneurysms, though results appear generally consistent between older and newer trials [87, 90, 91].
Justification
The panel did not make a recommendation regarding the use of TXA in SAH. The effects of TXA appear mixed, with a decreased risk of rebleeding, and a similar magnitude of increased stroke (both of which are themselves of uncertain clinical relevance in the context of these older studies in which diagnostic procedures may vary). Overall, there appears to be little impact upon mortality and the risk of poor functional outcome, although the evidence is insufficiently precise to rule out a clinically meaningful effect. The panel judged the available evidence as insufficient to make a recommendation, as the values and preferences of patients and clinicians regarding the risk of rebleeding vs. stroke may vary, such as when securement of aneurysm may be delayed.
Implementation issues
Given the uncertainty of the evidence and variations in local practice, decisions around the use of TXA in the population need be based upon individual factors, such as clinician concerns around risk of stroke vs. rebleeding, and time until definitive securement of aneurysm. Widespread use of TXA in this setting should await further evidence.
TXA in patients with non-traumatic intracranial hemorrhage.
Recommendation | |
|---|---|
We make no recommendation regarding the use of TXA in critically ill patients non-traumatic intracranial hemorrhage (No recommendation, moderate certainty). |
Evidence summary
Three RCTs have evaluated IV TXA in non-traumatic ICH, the majority of data from the large TICH-2 trial which evaluated IV TXA in the acute phase of patients with ICH [95‐97]. These studies demonstrate no change in mortality (RR 1.02, 95% CI 0.88–1.19; RD 0.4%, 95% CI − 2.5 to 4, moderate certainty), poor functional outcome (RR 0.98, 95% CI 0.93–1.04; RD − 1.4%, 95% CI − 4.9 to 2.8; moderate certainty). Other outcomes, including stroke, myocardial infarction, venous thromboembolism, seizure, and length of stay were also similar, although certainty was only moderate for all outcomes, limited my imprecision.
Justification
While the quality of evidence for critical outcomes was moderate, the point effect and confidence intervals for TXA did not indicate either benefit or harm in patients with ICH. There is thus moderate evidence of no effect, but the use or non-use of TXA in this setting would be reasonable pending further evidence. The panel thus chose to make no recommendation for or against the use of TXA compared to no TXA in this setting.
Implementation issues
Further evidence is required before changes in practice regarding TXA use should be considered. Decisions around the use of TXA should recognize that the effects of TXA in this population remain uncertain.
Recommendation | |
|---|---|
We suggest not using high-dose IV TXA in critically ill patients with gastrointestinal bleeding (Conditional recommendation, high certainty evidence). | |
We make no recommendation regarding the use of low-dose IV TXA or enteral TXA in critically ill patients with gastrointestinal bleeding (No recommendation, moderate certainty evidence). |
Evidence summary
Five studies, including the large HALT-IT trial [98] evaluated high-dose IV TXA (4 g/24 h or greater) [98‐102], finding no difference in mortality (RR 0.98, 95% CI 0.88–1.09; RD − 0.2%, 95% CI − 1.1 to 0.8, high certainty), rebleeding (RR 0.92, 95% CI 0.82–1.04; RD − 0.7%, 95% CI − 1.5 to 0.3; high certainty), or need for surgical intervention (RR 0.91, 95% CI 0.76–1.09; RD − 0.3%, 95% CI − 0.8 to 0.3%; high certainty). Increased rates of deep vein thrombosis (DVT) (RR 2.10, 95% CI 1.08–3.72; RD 0.2%, 95% CI 0–0.6; high certainty) and pulmonary embolism (PE) (RR 1.78, 95% CI 1.06–3; RD 0.3%, 95% CI 0–0.7; high certainty) as well as seizures (RR 1.73, 95% CI 1.03–2.93, RD 0.3%, 95% CI 0–0.7; high certainty) were noted, though the absolute number of these events was very small.
Seven studies evaluated low-dose IV and enteral TXA, [99‐106] finding a reduction in rebleeding (RR 0.5, 95% CI 0.38–0.88; RD − 8.1%, 95% CI − 10.9 to − 4.1%, moderate certainty) and need for surgical intervention (RR 0.58, 95% CI 0.38–0.88; RD -6.9%, 95% CI − 10.2 to − 2%; moderate certainty), and possibly a reduction in mortality at longest follow up (RR 0.62, 95% CI 0.36–1.09; RD − 2.6%, 95% CI − 4.4 to 0.6, moderate certainty); however, these results are limited by imprecision.
Justification
There is high certainty of harms with use of high-dose IV TXA and no clear benefit with its general use in gastrointestinal hemorrhage. Though the subgroup analysis suggests low-dose/enteral TXA may be helpful, the included studies are small and results imprecise; furthermore data on potential harms (DVT, PE, seizure) were not reported in most of these trials. While the quality of evidence for critical outcomes was moderate, the panel judged that the lack of data on the potential adverse effects of TXA in GI bleeding, especially in light of the harms seen in the HALT-IT trial, were insufficient to make a recommendation for or against the use of lower dose or enteral TXA until more data are available.
Implementation issues
There may be a role for “rescue” TXA in patients with massive exsanguination or refractory hemorrhage, for whom the risk of death due to bleeding is very high unless hemostasis is achieved, as the risk of increased seizures and VTE would be less important. If used as rescue, lower doses than those used in the HALT-IT trial may reduce the risk of these complications, as these were not observed in trials evaluating lower doses of IV TXA (< 4 g IV/24 h).
Recommendation | |
|---|---|
We suggest the early use of TXA in critically ill patients with postpartum hemorrhage (Conditional recommendation, high certainty). |
Evidence summary
Two RCTs evaluating the use of TXA for postpartum hemorrhage [107, 108] found a small reduction in risk of death from hemorrhage (RR 0.81, 95% CI 0.65–1; RD − 0.4%, 95% CI − 0.7 to 0, high certainty) with no effect on overall mortality (RR 0.88, 95% CI 0.54–1.05; RD − 0.3%, 95% CI − 0.7 to 0.1; high certainty) or hysterectomy (RR 0.93, 95% CI 0.46–1.89; RD − 0.2%, 95% CI − 1.9 to 3.1; high certainty).
Justification
TXA may reduce deaths due to hemorrhage in critically ill patients with postpartum hemorrhage, without an impact on all-cause mortality. The absolute mortality effect of TXA in patients with post partum heamorrhage (PPH) is small (< 1%), but may be higher in the subset of women who are critically ill. Despite the very small size of the effect, given the young age and generally high baseline health status of these patients, even a small potential reduction in mortality is desirable, especially given the high certainty that TXA has minimal harmful effects, and its low cost and high acceptability by clinicians and patients.
Implementation issues
Low-dose TXA, 1 g IV, should be given as early as possible if there are concerns that the patient may have significant PPH or signs of shock, as data from WOMAN indicate that TXA is most likely to be helpful within 3 h of onset of bleeding [107].
Recommendation | |
|---|---|
We recommend the use of TXA in critically ill patients with bleeding post-cardiac surgery (Strong recommendation, high certainty). |
Evidence summary
Numerous RCTs have evaluated dosing strategies of TXA, summarized in a recent systematic review, including the largest trial by Myles et al. [109]. TXA had no effect upon mortality (RR 0.75, 95% CI 0.5–1.13; RD − 0.3%, 95% CI − 0.6 to 0.2; high certainty), but slightly lowered the amount of bleeding (MD − 268 mL, 95% CI − 315 mL to − 222 mL, high certainty), resulting in a reduction in the need for surgical intervention (RR 0.53, 95% CI 0.4–0.71; RD − 1.7%, 95% CI − 2.2 to − 1.1, high certainty) and transfusion (RR 0.67, 95% CI 0.6–0.74; RD − 16.3%, 95% CI − 19.7 to − 12.8, high certainty), but a small increased risk of seizure (RR 4.11, 95% CI 1.44–11.72; RD 0.4%, 95% CI 0.1–1.5; high certainty).
Justification
There is high certainty that TXA reduces the volume of bleeding, need for surgery, and transfusion risk in bleeding patients’ post-cardiac surgery; the reduced risk of reoperation is likely of major significance to most patients. While there is an increased risk of seizures, this is small (< 1%) and likely dose-dependent, with low incidence if given in low (< 4 g/24 h) doses. The panel judged that almost all patients would trade a reduced risk of reoperation and transfusion for this small increase, especially as the risk is likely smaller when TXA is given in lower doses.
Implementation issues
Given the risk of seizures with higher dose TXA, clinicians should aim to keep cumulative doses below 50 mg/kg, and exercise caution should be used before given TXA to patients with a known history of seizures and/or renal failure. Clinicians caring for patients with critically ill patients bleeding after cardiac surgery should evaluate the dose and timing of TXA given in the operating room to ensure that higher doses are not given.
Discussion
This international guideline provides guidance for clinicians caring for critically ill patients with massive and non-massive bleeding. The taskforce generated 26 clinical practice recommendations (2 strong recommendations, 13 conditional recommendations, 11 no recommendation), and identified 11 PICOs with insufficient evidence to make a recommendation as factors such as clinical effects, certainty of evidence, resource use, variation in patient and clinician values, and acceptability and feasibility of implementation were too varied to result in a consensus recommendation. A summary of recommendations can be found in Table 1, and identified research priorities in Table 2.
Table 1
Summary of recommendations
Table 2
Research priorities
Section | Research priorities |
|---|---|
Transfusion ratios in massive bleeding | More high-quality, randomized data of massive transfusion protocols including high-ratio transfusion vs. low-ratio transfusion are required in trauma and non-trauma patients with massive bleeding More RCT data on impacts of massive transfusion protocols guided by empiric transfusion ratios vs. guided by point of care testing |
Cold-stored platelets | RCTs involving conventional and cold-stored platelets are needed in patient populations where rapid control of hemorrhage is vital, such as trauma-associated or obstetric hemorrhage. Key outcomes include clinical and blood product use, effects on measured hemostatic parameters, and patient-important outcomes |
Prothrombin complex concentrate in massive bleeding | RCT data demonstrating the effects of prothrombin complex concentrate (± fibrinogen concentrate) vs. conventional massive transfusion protocols are needed in both trauma and non-trauma populations with massive bleeding |
Early fibrinogen replacement in massive bleeding | Large-scale trials, including clear fibrinogen testing strategies, targets, products (cryoprecipitate vs concentrate), and populations are needed to guide decisions on the role of fibrinogen early in resuscitation |
Thromboelastography vs conventional coagulation testing in massive bleeding | Trials comparing the use of thromboelastography to conventional coagulation testing protocols are needed to demonstrate the effects and economic impacts of implementing thromboelastography across a variety of patient populations with massive bleeding; these should incorporate transfusion protocols (eg. ratios, alternative blood products) |
Red blood cell transfusion | More research is needed on transfusions in patients undergoing vascular surgery, and other surgical populations at risk for significant bleeding and with cardiovascular comorbidities More research is needed on guiding transfusions in low-risk patients with bleeding, such as healthy postpartum women, and surgical patients with few comorbidities |
Restrictive vs. liberal platelet transfusion in non-massive bleeding | More studies are needed to examine the difference in the transfusion practice of a restrictive versus a liberal platelet transfusion practice in terms of outcomes, effects, patient values and preferences, as well as resources required to implement such strategies |
Restrictive vs liberal platelets in patients on antiplatelet medications | Further research is required to define the platelet transfusion strategy with the restrictive strategy being no platelet transfusion in other subgroups of patients with non-major bleeding patients This is an important research question as gastrointestinal bleeding is common and patients with cardiovascular diseases requiring antiplatelet therapy are increasing |
Fibrinogen in non-massive bleeding | Research is needed on which which triggers should be used for “early” or “empiric” fibrinogen administration in patients with bleeding, and specific targets for replacement (fixed dose vs. use of viscoelastic testing) |
Plasma in non-massive bleeding | Future research should focus on 1) targeted personalized trial of using any point of care testing to assess presence and type of coagulopathy and determine transfusion requirements compared to transfusing patients based on clinical presentation; 2) restrictive versus liberal plasma transfusion strategies in non-massively bleeding critically ill patients with a coagulopathy and 3) exploring the correction of coagulopathy versus non-correction of coagulopathy in non-massively bleeding critically ill patients |
Point of care vs conventional in non-massive bleeding | RCTs comparing transfusion strategies guided by point of care testing vs. conventional coagulation testing, with and without fixed ratio blood product transfusions are needed to determine whether thomboelastography improves patient outcomes and impacts blood product use in critically ill patients |
TXA in trauma and traumatic brain injury | More research is required to identify subgroups most likely to benefit from the use of TXA and the role of individualized patient use guided by thromboelastometry and conventional coagulation tests |
TXA in subarachnoid hemorrhage | More research is needed on the role of TXA in specific patient populations, eg. those with delayed or challenging aneurysm securement |
TXA in intracranial hemorrhage | Given residual uncertainty around the effects of TXA on patient-important outcomes of mortality and functional recovery, further research is required. Other trials are planned or ongoing (NCT03385928, NCT02625948, NCT03044184, NCT02866838,ChiCTR1900027065), and will assist in addressing this area of uncertainty |
TXA in gastrointestinal bleeding | More evidence is required evaluating the role of enteral and low-dose intravenous TXA, and the potential role of TXA as rescue therapy in refractory hemorrhage |
TXA in postpartum | More research is needed on identifying which patients with PPH are most likely to benefit from TXA. For instance, it may be more helpful in patients with PPH after vaginal rather than caesarean delivery [38]. |
Anzeige
The strengths of this guideline include the breadth of expertise of the TF and rigorous GRADE methodology adherence. However, the guideline is not without limitations. First, the search was completed in September 2019, and ideally would be updated every 2 years. In light of the global pandemic, the completion of the guideline was delayed. Second, our systematic reviews were not registered a priori, as we adopted a rapid systematic review approach common in guideline methodology. Lastly, we did not have patient representation on the TF (Table 3).
Table 3
Ongoing trials of transfusion strategies in critically ill patients
PICO | Trial details | Participants | Comparisons | Primary Outcome(s) | Most recent status | |
|---|---|---|---|---|---|---|
Intervention | Control | |||||
Transfusion ratios | Evaluation of a transfusion therapy using whole blood in the management of coagulopathy in patients with acute traumatic hemorrhage (T-STORHM) NCT04431999 | Severe trauma patients requiring initiation of MHP, based on standardized criteria n = 200 | Whole blood for 1st and 2nd pack; then 3 PRBC, 3 plasma, 1 platelet | 3 PRBC, 3 plasma, 1 platelet | Noninferiority of coagulopathy correction (6 h); Mortality (day 2, 30); Mortality/ morbidity (24 h); Time to blood; Time to infusion; Coaguloapthy evolution; Cost | Not yet recruiting (Feb 9, 2021) |
Prothrombin complex vs plasma | Factor replacement in surgery (FARES) NCT04114643 | Patients undergoing cardiac surgery with or without CBP, who require coagulation factor replacement in the OR n = 103 | PCC | FFP | Treatment response (4 h, 24 h); number of transfusions (24 h); number who do not receive RBC transfusion | Active, not recruiting (November 3, 2020) |
PCC vs FFP | PCC vs FFP for post-cardiopulmonary bypass coagulopathy and bleeding NCT02557672 | Adults undergoing cardiac surgery with CPV, excessive microvascular bleeding n = 100 | PCC 15 u/kg | FFP 10–15 mL/kg | Blood loss (24 h); blood transfusions (24 h) | Enrolling (January 27, 2021) |
Prothrombin complex & fibrinogen vs plasma | factor in the initial resuscitation of severe trauma 2 patients (FiiRST-2) NCT04534751 | Severly injured adult trauma patients (age > 16) with massive hemorrhage protocol within first hour of hospital arrival n = 350 | PCC 2000 IU & fibrinogen concentrate 4 g in first and second MHP packs | FFP | Composite of total number of allogenic blood products within 24 h; total PRBCs transfused; thrombotic events (venous or arterial); ventilator-free days | Recruiting, April 5, 2021 |
Thromboelastography; PCC vs FFP | Patient blood management for massive obstetric hemorrhage NCT03784794 | Patients with severe obstetric hemorrhage of any cause n = 100 | Thromboeslastography guided transfusion of RBC, fibrinogen,PCC, platelets, RBCs | Conventional coagulation test driven tranfusion with RBC, platelet, FFP, cryoprecipitate | Number of transfusions (24 h), types (24 h); hospital mortality, bleeding control; ICU LoS, surgical intervention, TACO, TRALI, infection | Recruiting (March 3, 2020) |
Fibrinogen replacement | Transfusion of red blood cells, tranexamic acid and fibrinogen concentrate for severe trauma hemorrhage at prehospital phase of care. (PRETIC) NCT03780894 | Adults with severe trauma, bleeding/high bleeding suspicion, predicted need for transfusion n = 60 | 2 g fibrinogen concentrate; 1 g TXA; 2 RBCs prehospital phase of care | Standard care (TXA 1 g) | Coagulopathy as measured with TEG; mortality (1 h, 6 h, 24 h, 30d); Transfusions (24 h); VTE (30d); fluids, fluid balance; ventilator-free days | Recruiting (January 18, 2020) |
A multi-center, randomized, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma hemorrhage requiring major hemorrhage protocol (MHP) activation NCT04704869 | Adults with severe traumatic injury with ongoing active hemorrhage and requiring activity of MHP n = 1500 | Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) | Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) | Mortality (6 h, 24 h, 6 months, 12 months); death from bleeding (6 h, 24 h); transfusion requirements; QoL; ventilation, ICU, and hospitalization duration | Recruiting (January 12, 2021) | |
Transfusion of red blood cells, tranexamic acid and fibrinogen concentrate for severe trauma hemorrhage NCT04149171 | Adults with severe trauma and bleeding or high suspicion of bleeding n = 30 | RBC, Fibrinogen concentrate, TXA | Crystalloids, TXA | RBCs delivered, transfused | Recruiting (November 4, 2019) | |
Adjusted fibrinogen replacement strategy (AdFIrst) NCT03444324 | Adults with spine surgery and expected major blood loss, intra-op blood loss > 1L with need for FFP n = 200 | BT524 human fibrinogen concentrate | FFP | Intra-op blood loss; transfusion requirements; correction of fibrinogen; 24 h blood loss; re-bleed; hospital length of stay; mortality (hospital); adverse events; VTE | Recruiting (July 25, 2019) | |
Fibrinogen concentrate in isolated traumatic brain injury NCT03304899 | Severe isolated TBI with serum fibrinogen less than 200 mg/dL n = 50 | Weight based fibrinogen concentrate | No fibrinogen | Mortality; progression of intracranial hemorrhage, serum fibrinogen levels, VTE, myocardial infarction, transfusions | Unknown (February 27, 2019) | |
Fibrinogen in Haemorrhage of Delivery (FIDEL) NCT02155725 | Adult women with vaginal delivery, PPH requiring IV administration of prostaglandins n = 448 | 3 g fibrinogen concentrate IV | Placebo | Change in Hb > 4 g/dL or transfusion 2 PRBC; | Completed (September 25. 2020) | |
Pilot randomized trial of fibrinogen in trauma haemorrhage NCT02344069 | Adult trauma patient with need for transfusion, predicted need for MHP n = 40 | Fibrinogen concentrate | Placebo | TEG, transfusions, time to transfusion, need for surgery, VTE, anaphylaxis, mortality (24 h, 30d) | Completed (April 2017) | |
Thromboelastography | Use of ROTEM intraoperatively in women with placenta accreta (ROTEM) NCT02729974 | Women with placenta accrete with scheduled delivery by caesarian section n = 40 | ROTEM-guided transfusion | Conventional coagulation testi-guide transfusion | Transfusions (up to day 10); length of stay (ICU, hospital); surgical site infection; readmissions | Enrolling (January 21, 2020) |
TXA in PPH | NCT03475342 (Recruiting); NCT04350645 (Active, not recruiting); NCT03069859 (Recruiting); NCT03364491(Recruiting); NCT04707950 (Recruiting); NCT04427618 (Recruiting); NCT04733157 (Not yet recruiting); NCT04274335 (Recruiting); NCT04518163 (Recruiting); NCT02797119 (Recruiting); NCT04463966 (Recruiting); NCT03778242 (Recruiting); NCT03774524 (Recruiting); NCT03777878 (Recruiting); NCT03863964 (Active not recruiting); NCT03287336 (Active, not recruiting) | |||||
TXA in ICH | NCT04742205 (Not yet recruiting); NCT03044184 (Recruiting)l NCT03385928 (recruiting); NCT02866838 (Recruiting) | |||||
TXA in cardiac surgery | BCT04290884 (Recruiting) | |||||
TXA in SDH | NCT03353259 (Recruiting); NCT03582293 (Recruiting); NCT02568124 (Recruiting) | |||||
TXA in GI bleeding | NCT04489108 (Recruiting) | |||||
TXA in trauma | NCT02187120 (Recruiting) | |||||
In general, the evidence supporting transfusion practice in patients with massive or non-massive bleeding does not provide high certainty of effects for many outcomes. Current practice is often driven by transfusion thresholds which are based upon physiologic extrapolation and confounded observational evidence. For instance, although there are numerous studies evaluating transfusion ratios in massive hemorrhage, we were only able to identify two RCTs, which demonstrated more modest findings than the observational evidence, and no RCTs evaluating transfusion ratios outside of the trauma population, despite the widespread practice of incorporating high-ratio transfusion into hospital massive transfusion protocols. Given the large number of lives lost and resources spent caring for critically ill patients with bleeding, there is an urgent need for high-quality evidence to guide clinicians. In addition, many studies evaluated specific subpopulations of critically ill patients, resulting in gaps in areas where the task force did not believe extrapolation of indirect evidence to develop a general recommendation was justified.
Conclusions
This clinical practice guideline provides a summary of evidence and clinical guidance for transfusion in critically ill patients with massive and non-massive bleeding and identifies areas where further research is needed.
Acknowledgements
The Guidelines in Intensive Care Development and Evaluation (GUIDE) group provided methodological support throughout the guideline development process. We also thank Gordon Guyatt for his mentorship.
Anzeige
Declarations
Conflicts of interest
None.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.